| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
NewAmsterdam Pharma Company N.V
13D/A
NAMS · N62509109
|
8.7% |
9/22/2026
Event 9/18/2026
|
||||
| Frazier Life Sciences X, L.P. | 6.1% | |||||
| Frazier Lifesciences Sponsor LLC | 3.3% | |||||
| FHMLS X, L.P. | 6.1% | |||||
| FHMLS X, L.L.C. | 6.1% | |||||
| Frazier Life Sciences Public Fund, L.P. | 8.7% | |||||
| FHMLSP, L.P. | 8.7% | |||||
| FHMLSP, L.L.C. | 8.7% | |||||
| Frazier Life Sciences XI, L.P. | 1.1% | |||||
| FHMLS XI, L.P. | 1.1% | |||||
| FHMLS XI, L.L.C. | 1.1% | |||||
| Frazier Life Sciences XII, L.P. | 0.3% | |||||
| FHMLS XII, L.P. | 0.3% | |||||
| FHMLS XII, L.L.C. | 0.3% | |||||
| James N. Topper | 6.1% | |||||
| Patrick J. Heron | 6.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.